CT-1 Mechanistic Evaluation of the Effects of Ranolazine on Ventricular Repolarization Luiz Belardinelli, MD VP, Drug Research and Pharmacological Sciences.

Slides:



Advertisements
Similar presentations
L’azione antiaritmica – The Anti-Arrhythmic Action
Advertisements

Stefano Severi C 3 MIG 7 maggio Introduzione It is well known that changes in serum calcium influence the cardiac electrical activity particularly.
Brugada’s Syndrome and Sudden Cardiac Death
Cardiovascular Disaster in Hemodialysis patients
SUDDEN DEATH IN VARIOUS POPULATIONS: IS GENDER A RISK FACTOR? 11 th International Symposium Heart Failure & Co Reggia di Caserta; April 29, 2011; 12:35.
Examining the Science Underlying Myocardial Ischemia.
Aims Introduction to the heart.
Mechanisms of cardiac arrhythmias
Proarrhythmic Assessment of Drugs: The Need For a New Paradigm Philip Sager, MD, FACC, FAHA, FHRS Consulting Professor of Medicine Stanford University.
The link between non-clinical and clinical testing ~ are non-clinical tests predictive of clinical effects? C Mike Perkins MD Pfizer Global Research &
Cardiac Arrhythmias.
Heart Remember or cardiac memory.  Background Can heart remember?
1 Mechanism of Action Greg Beatch, Ph.D. Vice President, Scientific Affairs Cardiome Pharma Corp.
Drugs used to treat cardiac arrhythmias
Ventricular Arrhythmias Terry White, RN, EMT-P. Analyze the Rhythm.
Evaluation of Cardiac Safety by ECG Findings: Focus on QTc Duration Joel Morganroth, M.D. Clinical Professor of Medicine University of Pennsylvania Chief.
Copyright © The McGraw-Hill Companies, Inc. Permission required for reproduction or display. 1 CHAPTER 23 Antiarrhythmic Drugs.
The Need for a New Paradigm to Assess Proarrhythmic Effects of Drugs Philip Sager, MD, FACC, FAHA, FHRS Pharmaceutical Consultant Consulting Professor.
CARDIOVASCULAR SYSTEM PHYSIOLOGY. Pulmonary circulation: Path of blood from right ventricle through the lungs and back to the heart. Systemic circulation:
CR-1 1 Ranolazine Benefit/Risk Jeremy N. Ruskin, MD, FACC.
Eric Prystowsky, MD Director Clinical Electrophysiology Laboratory St Vincent Hospital Indianapolis, IN Dan Roden, MD Director Division of Clinical Pharmacology,
CARDIAC ARRHYTHMIA Catherine Seger Medicinal Chemistry.
Guyton 2011 pages Berne 2008 pages
The Basics of ECG Interpretation Dr Tim Smith. Summary Cardiac conducting system and the ECG waveform Cardiac conducting system and the ECG waveform The.
Disclosures Dr Scirica has received Dr Scirica has received honoraria for educational presentations (modest) from CV Therapeutics The study was supported.
Case presentation Torsade de Pointes. C15 Case Mr X presented to ED from Bosbokrandt (Nelspruit area) visiting in CPT. He is previously well 28yr old.
Different Mechanisms Linking Heart Failure to Arrhythmias Wojciech Zareba, MD, PhD Professor of Medicine/Cardiology University of Rochester Medical Center.
SS-1 Ranexa™ Supportive Slides 18. SS-2 Exercise Duration at Trough at Wk 12 (LOCF) by Background Therapy CARISA (CVT 3033) Treatment by background therapy.
CI-1 Ranexa™ (ranolazine) Extended Release Tablets Michael Sweeney, MD, FRCP VP, Medical Affairs CV Therapeutics, Inc. Cardiovascular and Renal Drugs Advisory.
Long QT and TdP Morning Report Elias Hanna, LSU Cardiology.
BIMM118 Cardiac Arrhythmia Arrhythmias : Abnormal rhythms of the heart that cause the heart to pump less effectively Arrhythmia occurs: –when the heart’s.
1 Proarrhythmic Assessment of Drugs: The Need For a New Paradigm Philip Sager, MD, FACC, FAHA, FHRS Consulting Professor of Medicine Stanford University.
稳心颗粒抗室性心侓失常的机制 Gan-Xin Yan Professor, Lankenau Institute for Medical Research Professor of Medicine, Thomas Jefferson University.
Cardiovascular Drugs That Prolong The QT Interval
Section 3 Lecture 3 Antiarrhythmic Drugs Heart beats (HB) originate from AV node Normal 70 beats/min at rest Arrhythmia (dysrhythmia): Abnormal.
András Varró Department of Pharmacology and Pharmacotherapy University of Szeged, Hungary Albert Szent-Györgyi Medical Center 2007 The importantance of.
Electrocardiography (ECG, EKG)
ECG Part II. Rate-measure of frequency of occurrence of cardiac cycles(b/m) < 60 beats/min is a bradycardia beats/min is normal >100 beats/min.
Drug Induced Arrhythmia
ELECTROCARDIOGRAM An electrocardiogram (EKG or ECG) is a graphic representation of the heart’s electrical activity.
23 Antiarrhythmic Drugs.
Effects of Ranolazine: from Angina to Cardiac Performance Iacopo Olivotto, MD Referral Center for Cardiomyopathies Careggi University Hospital Florence,
New Mechanistic Approaches to Myocardial Ischemia.
EKG’s Kelly Marchant RN July 28, 2015 Adapted from NURO 438
Arrhythmias. Cardiac dysrhythmia Cardiac dysrhythmia (arrhytmia) Abnormal electrical activity in the heart.
Differences in cardiac atrial and ventricular ion channels Norbert Jost, PhD Department of Pharmacology & Pharmacotherapy, University of Szeged Division.
Acquired Long QT Syndrome by Antiarrhythmic Drugs Chen Liying MD – Cardiology Department An Zhen Hospital Beijing CHINA. NASPE-Heart Rhythm Association.
Cardiac Arrhythmia.
1 AF: Issues with Anticoagulation AFL: Anticoagulation like AF When undergoing procedures with risk for bleeding: May DC warfarin for up to one week without.
Arrhythmia Arrhythmias are abnormal beats of the heart.
Antiarrhythmic Drugs.
Cardiovascular Cardiovascular pharmacology pharmacology.
Date of download: 6/2/2016 Copyright © The American College of Cardiology. All rights reserved. From: Electropharmacological characterization of cardiac.
Ann Intern Med. 1995;122(9): doi: / Figure Legend:
New interpretation of fractionated electrogram (EG) activity and late potentials. Desynchrony in the appearance of the epicardial action potential second.
Electrocardiogram (ECG) of a patient with prolonged QT and episodes of torsade de pointes ventricular tachycardia (VT). A. Twelve-lead ECG showing a heart.
Multiple Mechanisms in the Long-QT Syndrome
Cardiac ion channels in health and disease
ΑΣΘΕΝΗΣ ΜΕ ΚΟΙΛΙΑΚΕΣ ΑΡΡΥΘΜΙΕΣ
Molecular and Cellular Mechanisms of Cardiac Arrhythmias
Volume 10, Issue 1, Pages (January 2013)
Antiarrhythmic drugs [,æntiə'riðmik] 抗心律失常药
Volume 13, Issue 11, Pages (November 2016)
Chapter 30 Antiarrhythmic Drugs
Antiarrhythmic Drugs Types of Cardiac Arrhythmias:
Complexity of ranolazine and phenytoin use in an infant with long QT syndrome type 3  Reina Bianca Tan, MD, Sujata Chakravarti, MD, Melissa Busovsky-McNeal,
Arrhythmias Simple-dysfunction cause abnormalities in impulse formation and conduction in the myocardium. However, in clinic it present as a complex family.
Implications for safe medication prescribing in older adults
Drugs used in the treatment of arrhythmia I
Presentation transcript:

CT-1 Mechanistic Evaluation of the Effects of Ranolazine on Ventricular Repolarization Luiz Belardinelli, MD VP, Drug Research and Pharmacological Sciences CV Therapeutics, Inc.

CT-2 QT Prolongation Alone Does Not Predict Torsade de Pointes (TdP) Increase in QTc Interval, msec Incidence of TdP, % A better surrogate of pro-arrhythmic potential is needed. Canine chronic AV node block model—Vos MA, et al. Circulation. 1998;98: Almokalant d-SotalolDofetilide Amiodarone

CT-3 Repolarizing current Action Potential Duration (APD) Early afterdepolarizations ↑ Dispersion of repolarization Torsade de Pointes SubstrateTrigger Drug-Induced Torsade de Pointes— Relationship to EADs and Dispersion   2 Long QT 3 4 (EADs) 1 I Kr Long QT EADs ↑ DISPERSION Torsade de Pointes

CT-4 3 EADs  Ectopic Beats Extrasystoles Initiating beats for torsade EADs  APD (  QT) EADs AP Ectopic beats ECG  Inward current (eg. I Na, I Ca )

CT-5 I Kr blocker † †d-Sotalol (I Kr blockers) 100 µM. LV wall Epicardium Mid-myocardium Endocardium LV chamber Transmural Differences of Ventricular Repolarization—A Mechanism for Arrhythmias Normal 4 APD, msec Arrhythmias enabled Shimizu et al. JCE. 1999;10: Dispersion 59

CT-6 The Effects of Ranolazine On: Ion currents Ventricular AP (and QT) EADs Dispersion of ventricular repolarization Models Single myocytes Cardiac tissue Isolated hearts Anesthetized dogs Humans Conditions (risk factors) Bradycardia (pauses) Electrolytes (  K o,  Mg o ) Gender (female) “Ion channel mutations” With Isoproterenol Disease (eg, CHF, ischemia)

CT-7 Ion current Effect on action potential Effect on ECG Ranolazine potency IC 50 I Kr inhibitionLengthens  QT 12 µM Late I Na inhibitionShortens  QT ≥ 5 µM Average therapeutic concentration range 850 to 2500 ng/mL (~2 to 6 µM) Late I Na effect mitigates I Kr effect Ion Current Effects—I Kr and Late I Na 1

CT-8 Ranolazine Prolongs APD and QT Interval but This Effect Is Not Heart Rate Dependent 2 ↑APD 90, msec Pacing rate, b/min Ranolazine (5 µM) E-4031 (1 µM) Slope = Slope = †Okada et al. J Am Coll Cardiol. 1996;27: MARISA (CVT 3031). A. Isolated hearts E-4031DofetilideRanolazine Change with drug,  slope QT vs heart rate B. Humans † Dofetilide-like I Kr blocker

CT-9 EADs Ectopic beats torsade  Ranolazine Does Not Induce Early Afterdepolarizations (EADs) 3 XXX †With 3 nM ATX. 1. I Kr blockers (d-sotalol, E-4031) - LQT2 2. I Ks blocker (chromanol 293B † ) - LQT1 3. Late I Na enhancer (anemone toxin, ATX-II) - LQT3 Ranolazine reverses APD (and QT) prolongation, suppresses EADs and ventricular tachycardia (VT) caused by

CT-10 Ranolazine suppresses EADs induced by: quinidine, anenome toxin (ATX II), E-4031 Suppression by Ranolazine of d-Sotalol- Induced EAD in Purkinje Fiber Preparation Control d-Sotalol 50 µM EAD Ranolazine 5 µM Ranolazine 10 µM

CT-11 Ranolazine Suppresses Ectopic Beats, EADs, and VT Induced by I Kr Block in Female Rabbit Hearts B. Ranolazine (30 µM) Multi-channel Blocker A. Control 3-sec pause CT-11

CT-12 Ranolazine Suppresses Ectopic Beats, EADs, and VT Induced by I Kr Block in Female Rabbit Hearts C. E-4031 (60 nM) I Kr Blocker A. Control 3-sec pause CT-12

CT-13 d-Sotalol, 100 µM ATX-II, 20 nM Ranolazine ATX-II d-Sotalol Canine LV wedge. BCL = 2000 msec. Ranolazine Does Not Increase Transmural Dispersion of Repolarization (TDR) NS TDR, msec 4 mM [K] o Ranolazine, µM

CT-14 EADs and Increased Dispersion of Ventricular Repolarization Predicts the Occurrence of TdP in Humans Drug evaluated Drug action in canine LV myocardium TdP reported in humans Induces EADs Increases TDR Quinidine (≤ 5 µM) +++ d-Sotalol +++ Terfenadine +++ Erythromycin +++ Cisapride +++ Sodium pentobarbital ––– Ranolazine –– ↓I Kr → ↑APD and QT

CT-15 Summary  Drugs that cause torsade de pointes –Prolong APD/QT –Induce EADs –Augment the dispersion of repolarization present in the normal heart  Ranolazine, 1 to 100 µM, prolongs APD & QT, but –Does not induce EADs –Does not increase dispersion of ventricular repolarization –Suppresses the arrhythmic effects of a number of QT-prolonging drugs –Would not be expected to cause torsade de pointes